Literature DB >> 19629567

Charcot–Marie–Tooth disease type 2J with MPZ Thr124Met mutation: clinico-electrophysiological and MRI study of a family.

Elena Gallardo1, Antonio García, César Ramón, Elías Maraví, Jon Infante, Itziar Gastón, Ángel Alonso, Onofre Combarros, Peter De Jonghe, José Berciano.   

Abstract

The purpose of the present study was to describe clinico-electrophysiological features and lower limb muscle MRI findings in a CMT2J pedigree due to MPZ Thr124Met mutation. We examined the proband, aged 56 years, and her affected daughter and son, aged 30 and 29 years. Disease severity in terms of ability to walk and run was established using a nine-point functional disability scale (FDS). We administered the CMT neuropathy score (CMTNS) based on patient's symptoms, neurologic examination and neurophysiologic testing. All three patients had non-symptomatic Adie's pupil. The proband and her son presented with late-onset lower limb sensorimotor neuropathy and pes cavus; the proband's daughter had no signs of polyneuropathy. FDS score was 4 in the proband, 2 in her son, and 0 (normal) in her daughter. In both symptomatic patients, electrophysiological study showed a pattern of length-dependent axonal neuropathy mainly involving lower limb nerves; this was normal in the other patient. CMTNS was 18 in the proband, 12 in her son, and 0 (normal) in her daughter. MRI of foot and leg musculature was normal in the proband's daughter, whereas the other two patients showed massive fatty atrophy of intrinsic foot musculature, extensive and diffuse fatty atrophy of leg muscles in the proband, and mild distally accentuated fatty infiltration of calf muscles in her son. Muscle edema, detected only in the proband's son, was present in 7 out of 22 (33%) of visualized leg muscles, whereas contrast enhancement occurred in 6 of them. The reported mutation may manifest with either isolated Adie's pupil or pupil abnormalities with late-onset sensorimotor length-dependent axonal polyneuropathy, though the presence of pes cavus might indicate an earlier onset. MRI examination helps to delineate an accurate extent of muscle involvement in the disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19629567     DOI: 10.1007/s00415-009-5251-y

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  44 in total

Review 1.  MR imaging in nonneoplastic muscle disorders of the lower extremity.

Authors:  Joshua M Farber; Kenneth A Buckwalter
Journal:  Radiol Clin North Am       Date:  2002-09       Impact factor: 2.303

2.  Case records of the Massachusetts General Hospital. Case 18-2006. A 57-year-old woman with numbness and weakness of the feet and legs.

Authors:  William J Triggs; Robert H Brown; Daniel L Menkes
Journal:  N Engl J Med       Date:  2006-06-15       Impact factor: 91.245

3.  Reliability and validity of the CMT neuropathy score as a measure of disability.

Authors:  M E Shy; J Blake; K Krajewski; D R Fuerst; M Laura; A F Hahn; J Li; R A Lewis; M Reilly
Journal:  Neurology       Date:  2005-04-12       Impact factor: 9.910

4.  An axonal form of Charcot-Marie-Tooth disease showing distinctive features in association with mutations in the peripheral myelin protein zero gene (Thr124Met or Asp75Val).

Authors:  K Misu; T Yoshihara; Y Shikama; E Awaki; M Yamamoto; N Hattori; M Hirayama; T Takegami; K Nakashima; G Sobue
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-12       Impact factor: 10.154

5.  Clinical and pathological phenotype of the original family with Charcot-Marie-Tooth type 1B: a 20-year study.

Authors:  T D Bird; G H Kraft; H P Lipe; K L Kenney; S M Sumi
Journal:  Ann Neurol       Date:  1997-04       Impact factor: 10.422

6.  Autonomic and respiratory dysfunction in Charcot-Marie-Tooth disease due to Thr124Met mutation in the myelin protein zero gene.

Authors:  T Stojkovic; J de Seze; O Dubourg; M C Arne-Bes; S Tardieu; J C Hache; P Vermersch
Journal:  Clin Neurophysiol       Date:  2003-09       Impact factor: 3.708

7.  Denervated human skeletal muscle: MR imaging evaluation.

Authors:  J L Fleckenstein; D Watumull; K E Conner; M Ezaki; R G Greenlee; W W Bryan; D P Chason; R W Parkey; R M Peshock; P D Purdy
Journal:  Radiology       Date:  1993-04       Impact factor: 11.105

Review 8.  Phenotypic clustering in MPZ mutations.

Authors:  Michael E Shy; Agnes Jáni; Karen Krajewski; Marina Grandis; Richard A Lewis; Jun Li; Rosemary R Shy; Janne Balsamo; Jack Lilien; James Y Garbern; John Kamholz
Journal:  Brain       Date:  2004-01-07       Impact factor: 13.501

9.  Magnetic resonance imaging signal changes in denervated muscles after peripheral nerve injury.

Authors:  G A West; D R Haynor; R Goodkin; J S Tsuruda; A D Bronstein; G Kraft; T Winter; M Kliot
Journal:  Neurosurgery       Date:  1994-12       Impact factor: 4.654

10.  Two novel mutations in dynamin-2 cause axonal Charcot-Marie-Tooth disease.

Authors:  G M Fabrizi; M Ferrarini; T Cavallaro; I Cabrini; R Cerini; L Bertolasi; N Rizzuto
Journal:  Neurology       Date:  2007-07-17       Impact factor: 9.910

View more
  8 in total

1.  MRI findings, patterns of disease distribution, and muscle fat fraction calculation in five patients with Charcot-Marie-Tooth type 2 F disease.

Authors:  Michele Gaeta; Achille Mileto; Anna Mazzeo; Fabio Minutoli; Rita Di Leo; Nicola Settineri; Rocco Donato; Giorgio Ascenti; Alfredo Blandino
Journal:  Skeletal Radiol       Date:  2011-05-25       Impact factor: 2.199

2.  Reduced penetrance in hereditary motor neuropathy caused by TRPV4 Arg269Cys mutation.

Authors:  José Berciano; Jonathan Baets; Elena Gallardo; Magdalena Zimoń; Antonio García; Eduardo López-Laso; Onofre Combarros; Jon Infante; Vincent Timmerman; Albena Jordanova; Peter De Jonghe
Journal:  J Neurol       Date:  2011-02-19       Impact factor: 4.849

3.  Charcot-Marie-Tooth 2F: phenotypic presentation of the Arg136Leu HSP27 mutation in a multigenerational family.

Authors:  Claudia Stancanelli; Gian Maria Fabrizi; Moreno Ferrarini; Tiziana Cavallaro; Federica Taioli; Rita Di Leo; Massimo Russo; Luca Gentile; Antonio Toscano; Giuseppe Vita; Anna Mazzeo
Journal:  Neurol Sci       Date:  2014-12-30       Impact factor: 3.307

4.  Long-term analyses of innervation and neuromuscular integrity in the Trembler-J mouse model of Charcot-Marie-Tooth disease.

Authors:  Jessica Renee Nicks; Sooyeon Lee; Kathryne Ann Kostamo; Andrew Benford Harris; Amanda M Sookdeo; Lucia Notterpek
Journal:  J Neuropathol Exp Neurol       Date:  2013-10       Impact factor: 3.685

Review 5.  New evidence for secondary axonal degeneration in demyelinating neuropathies.

Authors:  Kathryn R Moss; Taylor S Bopp; Anna E Johnson; Ahmet Höke
Journal:  Neurosci Lett       Date:  2020-12-24       Impact factor: 3.046

6.  A Novel Asp121Asn Mutation of Myelin Protein Zero Is Associated with Late-Onset Axonal Charcot-Marie-Tooth Disease, Hearing Loss and Pupil Abnormalities.

Authors:  Xiaohui Duan; Weihong Gu; Ying Hao; Renbin Wang; Hong Wen; Shaojie Sun; Jinsong Jiao; Dongsheng Fan
Journal:  Front Aging Neurosci       Date:  2016-09-22       Impact factor: 5.750

7.  Proteome profile of peripheral myelin in healthy mice and in a neuropathy model.

Authors:  Sophie B Siems; Olaf Jahn; Maria A Eichel; Nirmal Kannaiyan; Lai Man N Wu; Diane L Sherman; Kathrin Kusch; Dörte Hesse; Ramona B Jung; Robert Fledrich; Michael W Sereda; Moritz J Rossner; Peter J Brophy; Hauke B Werner
Journal:  Elife       Date:  2020-03-04       Impact factor: 8.140

8.  Genotype-phenotype characteristics and baseline natural history of heritable neuropathies caused by mutations in the MPZ gene.

Authors:  Oranee Sanmaneechai; Shawna Feely; Steven S Scherer; David N Herrmann; Joshua Burns; Francesco Muntoni; Jun Li; Carly E Siskind; John W Day; Matilde Laura; Charlotte J Sumner; Thomas E Lloyd; Sindhu Ramchandren; Rosemary R Shy; Tiffany Grider; Chelsea Bacon; Richard S Finkel; Sabrina W Yum; Isabella Moroni; Giuseppe Piscosquito; Davide Pareyson; Mary M Reilly; Michael E Shy
Journal:  Brain       Date:  2015-08-25       Impact factor: 13.501

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.